We read with great interest the recently published article by Ortega et al 1 reporting sex-specific differences of glucocerebrosidase (GBA) gene mutation frequencies in carriers with Parkinson's disease (GBA-PD) of Ashkenazi Jewish ancestry. They observed unequal distribution of mutations' frequencies regarding their severity: female patients represented a smaller part of the GBA-PD cohort (approximately 40%), but interestingly, almost 80% of them carried severe GBA variants.In this letter, we report results for a cohort of 770 Serbian patients with PD. None of the participants were of Ashkenazi Jewish ancestry. Mutation analysis of GBA (exons 8-11), LRRK2 (exons 24, 25, 29-31, 35, 38, 40, and 41), and PARKIN (all exons) was performed in all patients (Table 1). GBA variants were found in only 90 patients (11.7%; 84 heterozygotes and 6 homozygotes/compound heterozygotes). GBA mutations were also found combined with LRRK2 or PARKIN variants in five patients (Table 1). We previously reported that frequency of GBA variants among Serbian patients with PD 2 was 5.8%; however, at that point, the analyzed cohort was smaller (360 patients with PD), and risk variants such as T369M were not included in the analysis.Among heterozygous GBA carriers, severe variants (D409H, L444P, L444R, R46C, and RecNciI) were the most frequent, found in 34.4%, followed by risk variant T369M in 30.0%, mild variant N370S in 13.3%, and null variants (del55bp, R463H, R359X) in 6.67%. Eight patients (8.9%) carried GBA variants of "unknown" severity (E388K, D380V, R368H, P391L, N392S, and E326K). Notably, one patient harboring the E326K variant was included in the latter group, because it is still unclear whether this variant is a benign polymorphism, mild mutation, or mutation of "unknown" severity. 3